← Research library

Tirzepatide

GLP-1 / metabolic · By Preptide Pro editorial team · Last updated

Tirzepatide is a glp-1 / metabolic peptide, and it has an FDA-approved product. A dual GIP and GLP-1 receptor agonist. Approved by the FDA for type 2 diabetes, chronic weight management and obstructive sleep apnea with obesity.

FDA-approved (see products)

Chemistry (PubChem)

PubChem CID166567236
CAS number2023788-19-2
Molecular formulaC225H348N48O68
Molecular weight4813 g/mol
Other namesTirzepatide, Mounjaro (TN), Zepbound (TN), Tirzepatide free base?, Tirzepatide (JAN/USAN), WLZ4518, BP-43671, D11360

Is Tirzepatide FDA-approved?

FDA application records from openFDA
BrandApplicationStatusSponsor
MOUNJARONDA215866PrescriptionELI LILLY AND CO
MOUNJARO KWIKPENNDA215866PrescriptionELI LILLY AND CO
MOUNJARO (AUTOINJECTOR)NDA215866PrescriptionELI LILLY AND CO
ZEPBOUNDNDA217806PrescriptionELI LILLY AND CO
ZEPBOUND KWIKPENNDA217806PrescriptionELI LILLY AND CO
ZEPBOUND (AUTOINJECTOR)NDA217806PrescriptionELI LILLY AND CO

How much research is there on Tirzepatide?

PubMed lists 2,737 records for “tirzepatide”, of which 148 are tagged as human clinical trials.

Sources

This is general research information, not medical advice. Check with a clinician before using any compound.

Preptide Pro is a tracking tool, not medical advice. Talk to a clinician about any treatment.